Intuitive Surgical stock kpis
Want to see ISRG full AI Analyst Report?
Revenue by Segment
Intuitive Surgical reported revenue by segment of $3.05B in Q3 2026, up 5.4% from Q2 2026 and up 21.7% year over year. This is the highest value since 2018.
Breaks revenue into systems, instruments & accessories, and services to show reliance on one-time system sales versus recurring consumables and support; a shift toward recurring revenue typically signals more stable, predictable cash flow.
Instruments & Accessories are the primary growth engine, with Services and Systems climbing behind strong da Vinci placements and ION adoption; recent quarters show accelerating recurring revenue and higher service revenue per system, validating the installed‑base monetization strategy. Key risks: the extended‑use instrument program and GLP‑1–driven bariatric declines could lower I&A revenue‑per‑procedure, and China/tender pressure may slow system placements. Sustained adoption of da Vinci 5 and system placements is the main lever to keep margins and recurring revenue growth intact.
ISRG Revenue by Segment
| Period | Services | Instruments and Accessories | Systems | Total |
|---|---|---|---|---|
| Q3 2026Sep 30, 2026 | $482.20M | $1.80B | $769.10M | $3.05B |
| Q2 2026Jun 30, 2026 | $472.40M | $1.73B | $685.00M | $2.89B |
| Q1 2026Mar 31, 2026 | $433.70M | $1.69B | $650.70M | $2.77B |
| Q4 2025Dec 31, 2025 | $422.00M | $1.66B | $785.90M | $2.87B |
| Q3 2025Sep 30, 2025 | $395.90M | $1.52B | $590.40M | $2.51B |
| Q2 2025Jun 30, 2025 | $391.20M | $1.47B | $574.70M | $2.44B |
| Q1 2025Mar 31, 2025 | $363.00M | $1.37B | $522.70M | $2.25B |
| Q4 2024Dec 31, 2024 | $347.40M | $1.41B | $654.60M | $2.41B |
| Q3 2024Sep 30, 2024 | $328.90M | $1.26B | $445.00M | $2.04B |
| Q2 2024Jun 30, 2024 | $317.30M | $1.24B | $448.20M | $2.01B |
| Q1 2024Mar 31, 2024 | $313.50M | $1.16B | $418.20M | $1.89B |
| Q4 2023Dec 31, 2023 | $304.40M | $1.14B | $480.20M | $1.93B |
| Q3 2023Sep 30, 2023 | $292.90M | $1.07B | $379.40M | $1.74B |
| Q2 2023Jun 30, 2023 | $287.00M | $1.08B | $393.00M | $1.76B |
| Q1 2023Mar 31, 2023 | $283.20M | $985.60M | $427.40M | $1.70B |
| Q4 2022Dec 31, 2022 | $263.30M | $940.70M | $451.00M | $1.66B |
| Q3 2022Sep 30, 2022 | $259.90M | $871.60M | $425.90M | $1.56B |
| Q2 2022Jun 30, 2022 | $251.70M | $895.30M | $375.10M | $1.52B |
| Q1 2022Mar 31, 2022 | $249.30M | $810.30M | $428.10M | $1.49B |
| Q4 2021Dec 31, 2021 | $238.00M | $842.80M | $469.90M | $1.55B |
| Q3 2021Sep 30, 2021 | $232.70M | $755.40M | $415.20M | $1.40B |
| Q2 2021Jun 30, 2021 | $228.00M | $796.40M | $439.60M | $1.46B |
| Q1 2021Mar 31, 2021 | $217.50M | $705.90M | $368.70M | $1.29B |
| Q4 2020Dec 31, 2020 | $215.40M | $746.90M | $366.80M | $1.33B |
| Q3 2020Sep 30, 2020 | $179.30M | $630.60M | $267.80M | $1.08B |
| Q2 2020Jun 30, 2020 | $130.30M | $460.80M | $261.00M | $852.10M |
| Q1 2020Mar 31, 2020 | $198.70M | $617.50M | $283.30M | $1.10B |
| Q4 2019Dec 31, 2019 | $190.30M | $671.20M | $416.20M | $1.28B |
| Q3 2019Sep 30, 2019 | $183.40M | $606.20M | $338.60M | $1.13B |
| Q2 2019Jun 30, 2019 | $176.60M | $578.50M | $343.80M | $1.10B |
| Q1 2019Mar 31, 2019 | $173.90M | $552.30M | $247.50M | $973.70M |
| Q4 2018Dec 31, 2018 | $166.60M | $539.30M | $340.60M | $1.05B |
| Q3 2018Sep 30, 2018 | $160.00M | $486.30M | $274.60M | $920.90M |
| Q2 2018Jun 30, 2018 | $155.80M | $476.10M | $277.40M | $909.30M |
| Q1 2018Mar 31, 2018 | $152.70M | $460.30M | $234.50M | $847.50M |

